3D BioFibR’s mission is to become a global leader in the production of nature’s strongest, lightest and toughest materials. By synthesizing these biofibers that cannot be directly harvested, at a scale and cost amenable to commercial use, we will enable the solution to several engineering challenges of our day.
A key milestone for our seed funding is finalizing commercial partnerships that validate how our unique technology can enable applications in biomedicine. Over the next 2-3 years, we will increase our manufacturing capability to meet commercial demand and work with industrial partners to co-develop and commercialize cutting-edge fiber-based products.
Our Sequence of Opportunities
One of the key challenges of a materials company is determining what projects to work on and which projects to put off into the future. Despite having success creating extremely strong spider silk with physical properties that exceeds any published comparable data, 3D BioFibR has chosen to focus first on collagen-based products for tissue engineering. Collagen fibers are the most abundant protein structure in the body and play a major structural role in all mammals. It is the natural “scaffold” that cells live on and the structural backbone of the majority of our tissues.
The market segments we have chosen to focus on are prioritized based on technical risk, market potential, and verified market interest. In order:
- CollaFibR™ for Bioinks. By using short collagen fibers as a bioink additive, our technology can increase the mechanical durability and cellular organization within 3D bioprinted constructs, driving this technology towards clinical applications
- CollaFibR™ for 3D Tissue Culture. We have created a prototype of a collagen fiber scaffold that can be used for 3D tissue culture, that solves critical end-user pain points by featuring a high batch-to-batch consistency, versatile analytical capability, and room temperature storage.
- CollaFibR™ for Tissue Engineering. We are working with multiple companies in the research tissue engineering space to increase the physiological relevance of their in-vitro tissue models, by replacing the synthetic scaffold at the base of their model, with a collagen based scaffold.